ANG Lifesciences India Ltd — Board Meeting, 30-05-2025: Board Meeting

ANG Lifesciences India Limited has announced a board meeting on to approve the financial results for the quarter and half-year. The company reported a standalone net loss of ₹10.34 Cr and a consolidated net loss of ₹12.41 Cr for the year, impacted by high finance costs and material expenses. Revenue declined to ₹89.91 Cr standalone and ₹92.85 Cr consolidated, mainly from pharmaceuticals. The balance sheet shows rising borrowings and current liabilities, while cash flow from operations remained negative. The auditors issued an unmodified opinion on both standalone and consolidated results. The business continues to focus on its pharmaceutical segment amid challenging profitability.